Published • loading... • Updated
MAIA Activates New Site for THIO-101 Phase II Trial
Summary by Verdict Hospital
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
MAIA activates new site for THIO-101 Phase II trial
MAIA Biotechnology has activated new US site, the Winship Cancer Institute of Emory University, and opened patient enrolment for the Phase II THIO-101 expansion trial evaluating its telomere-targeting agent, ateganosine, as a third-line therapy for NSCLC.The post MAIA activates new site for THIO-101 Phase II trial appeared first on Hospital Management.
Father's Day SaleGet 40% off Vantage subscriptions for yourself or a friend.Get Started
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
